Arbutus Biopharma Corp
ABUSNasdaq
$4.56
↓ -3.8%Jul 17 close · end-of-day
Price
1Y↑ +45.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$890.2M
Enterprise Value
$795.0M
P/E
5.5
P/S
4.6
P/B
3.4
EV/EBITDA
5.1
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$191.4M
Net Income (TTM)
$160.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
81.7%
Net Margin
84.0%
ROE
61.8%
ROIC
74.9%
Debt / Equity
0.0
Net Cash
$95.2M
Return 1Y
+45.2%
Company profile
Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.
- CEO
- William H. Collier
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Pennsylvania
- Website
- arbutusbio.com
Management & directors
- Androski LindsayPresident and CEO
- Nguyen TuanChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ABUS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$179.1M↑ +10054.5%
Diluted EPS$0.87↓ -769.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$57.8M | -$73.5M | -$65.5M | -$78.1M | -$76.3M | -$38.2M |
| Net income | -$63.7M | -$76.2M | -$69.5M | -$72.8M | -$69.9M | -$33.5M |
| Diluted EPS | -$1.00 | -$0.83 | -$0.46 | -$0.44 | -$0.38 | -$0.17 |
| Operating cash flow | -$51.4M | -$67.5M | -$35.4M | -$85.9M | -$64.8M | -$39.6M |
| Free cash flow | -$51.7M | -$68.3M | -$35.9M | -$86.9M | -$65.0M | -$39.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -836.1% | -669.1% | -167.8% | -430.5% | -1236.7% | -271.0% |
| Net margin | -922.0% | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.3M | $1.6M | $1.8M | $10.7M | $529,000.00 | $1.1M | $179.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.6M | -$21.4M | -$13.9M | -$25.7M | $1.5M | -$8.7M | -$5.3M | $168.9M |
| Net income | -$19.8M | -$19.7M | -$12.5M | -$24.5M | $2.5M | -$7.7M | -$3.8M | $169.7M |
| Diluted EPS | -$0.11 | -$0.10 | -$0.07 | -$0.13 | $0.01 | -$0.04 | -$0.01 | $0.87 |
| Operating cash flow | -$14.5M | -$20.7M | -$10.3M | -$13.4M | -$15.7M | -$5.8M | -$4.7M | -$8.1M |
| Free cash flow | -$14.5M | -$20.7M | -$10.4M | -$13.4M | -$15.7M | -$5.8M | -$4.7M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1250.5% | -1601.2% | -885.2% | -1456.9% | 13.9% | -1636.9% | -503.3% | 94.3% |
| Net margin | -1146.9% | -1472.5% | -796.2% | -1390.4% | 23.5% | -1463.5% | -357.4% | 94.7% |
Company news
Jul 20, 2026
Jul 17, 2026
Jul 16, 2026
- 4d agoABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?stocktwits.com
- 4d agoArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholdersfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-02 | Nguyen Tuan· Chief Financial Officer | Award | 73,500 | $0.00 | $0.00 | filing |
| 2026-02-02 | Androski Lindsay· President and CEO | Award | 28,000 | $0.00 | $0.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.